首页> 外文期刊>Therapeutics and Clinical Risk Management >Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
【24h】

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study

机译:依那西普或英夫利昔单抗对类风湿关节炎患者肝功能测试的其他影响:一项队列研究

获取原文
           

摘要

Purpose: One of the most important long-term side effects of therapy for rheumatoid arthritis (RA) is the elevation of liver function tests, with earlier studies reporting an elevation of more than 1× the upper limit of normal (1 × ULN). The current study expands the literature by comparing the trends of transaminase changes caused by conventional and biologic disease-modifying antirheumatic drugs (DMARDs). Patients and methods: The drug categories examined were methotrexate (MTX) and all other nonbiologic DMARDs. Where RA patients exhibited inadequate response to conventional DMARDs (cDMARDs), we added biologic DMARDs (bDMARDs) to the treatment. We compared the trend of changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the patients receiving MTX with the trend observed in the patients whose treatment encompassed both bDMARDs and MTX. The comparison was conducted using random intercept models, which are a type of linear mixed effects model. Results: This work involved 512 RA patients (MTX: 450, MTX + infliximab [INF]: 26, MTX + etanercept [ETA]: 36), whose ALT and/or AST levels were measured in 1,786 visits (MTX: 1,543, MTX + INF: 107, MTX + ETA: 136). ALT and/or AST elevations greater than 1 × ULN were observed in 344 (19.3%) visits (MTX: 295 [19.1%], MTX + INF/ETA: 49 [20.2%]). In this study, the trends of ALT and AST changes increased when receiving MTX, while the INF/ETA addition decreased these trends. The random intercept models indicated that changes in the mean ALT levels were significantly different over the time for MTX and MTX + INF/ETA groups (β [SE] =-0.190 [0.093], P = 0.040) but changes in the mean AST levels were nonsignificantly different over the time for such groups (β [SE] =-0.099 [0.064], P =0.120). Conclusion: Despite a higher incidence of elevated transaminases during the use of MTX + INF/ETA, the combination of INF/ETA with MTX reduced transaminase levels and returned ALT levels to normal concentrations.
机译:目的:类风湿关节炎(RA)的最重要的长期副作用之一是肝功能检查的升高,早期的研究报道其升高超过正常上限的1倍(> 1×ULN) 。当前的研究通过比较由传统和生物疾病修饰性抗风湿药(DMARDs)引起的转氨酶变化趋势来扩展文献。患者和方法:检查的药物类别为甲氨蝶呤(MTX)和所有其他非生物DMARD。当RA患者对常规DMARD(cDMARD)的反应不足时,我们在治疗中添加了生物DMARD(bDMARD)。我们将接受MTX的患者的丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)的变化趋势与同时接受bDMARD和MTX治疗的患者的趋势进行了比较。使用随机截距模型进行比较,该模型是线性混合效应模型的一种。结果:这项工作涉及512名RA患者(MTX:450,MTX +英夫利昔单抗[INF]:26,MTX +依那西普[ETA]:36),其ALT和/或AST水平在1786次就诊中进行了测量(MTX:1,543,MTX + INF:107,MTX + ETA:136)。在344(19.3%)次就诊中观察到ALT和/或AST升高大于1×ULN(MTX:295 [19.1%],MTX + INF / ETA:49 [20.2%])。在这项研究中,接受MTX时ALT和AST的变化趋势增加,而添加INF / ETA则降低了这些趋势。随机截距模型表明,MTX和MTX + INF / ETA组的平均ALT水平随时间变化显着不同(β[SE] = -0.190 [0.093],P = 0.040),但平均AST水平发生变化随时间推移,这些组的差异无统计学意义(β[SE] = -0.099 [0.064],P = 0.120)。结论:尽管在使用MTX + INF / ETA的过程中转氨酶升高的发生率较高,但INF / ETA与MTX的组合降低了转氨酶水平,并使ALT水平恢复到正常浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号